Ovarian mucinous cystadenocarcinoma
diseaseOn this page
Also known as mucinous cystadenocarcinoma of ovarymucinous cystadenocarcinoma of the ovaryovary mucinous cystadenocarcinoma
Summary
Ovarian mucinous cystadenocarcinoma (MONDO:0002701) is a disease and 21 clinical trials. Top therapeutic interventions include bevacizumab, belinostat, and denileukin diftitox. A subtype of ovarian cystadenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 21
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | ovarian mucinous cystadenocarcinoma |
| Mondo ID | MONDO:0002701 |
| EFO | EFO:1001963 |
| DOID | DOID:3604 |
| NCIT | C4026 |
| SNOMED CT | 254851009 |
| UMLS | C0279665 |
| MedGen | 76011 |
| GARD | 0023216 |
| Anatomy (UBERON) | UBERON:0000992 |
| Is cancer (heuristic) | no |
Also known as: mucinous cystadenocarcinoma of ovary · mucinous cystadenocarcinoma of the ovary · ovarian mucinous cystadenocarcinoma · ovary mucinous cystadenocarcinoma
Data availability: 22 cell lines.
Disease family
Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › ovarian adenocarcinoma › ovarian cystadenocarcinoma › ovarian mucinous cystadenocarcinoma
Related subtypes (2): ovarian clear cell cystadenocarcinoma, ovarian serous cystadenocarcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 21.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 10 |
| PHASE2 | 6 |
| PHASE3 | 2 |
| Not specified | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01081262 | PHASE3 | ACTIVE_NOT_RECRUITING | Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer |
| NCT01492920 | PHASE3 | WITHDRAWN | Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy |
| NCT02101775 | PHASE2 | ACTIVE_NOT_RECRUITING | Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT00004221 | PHASE2 | TERMINATED | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer |
| NCT00059787 | PHASE2 | COMPLETED | Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma |
| NCT00466960 | PHASE2 | COMPLETED | Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy |
| NCT00939809 | PHASE2 | COMPLETED | A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
| NCT00993616 | PHASE2 | COMPLETED | Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin |
| NCT02142803 | PHASE1 | ACTIVE_NOT_RECRUITING | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors |
| NCT00002913 | PHASE1 | COMPLETED | Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer |
| NCT00060359 | PHASE1 | COMPLETED | Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer |
| NCT00079430 | PHASE1 | COMPLETED | Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT00085358 | PHASE1 | COMPLETED | Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) |
| NCT00357448 | PHASE1 | COMPLETED | Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer |
| NCT00814086 | PHASE1 | COMPLETED | Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer |
| NCT01074411 | PHASE1 | COMPLETED | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
| NCT01233505 | PHASE1 | TERMINATED | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors |
| NCT01294293 | PHASE1 | COMPLETED | TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer |
| NCT02111941 | EARLY_PHASE1 | COMPLETED | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
| NCT01080521 | Not specified | COMPLETED | Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy |
| NCT01275664 | Not specified | TERMINATED | Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BEVACIZUMAB | 4 | 4 |
| BELINOSTAT | 4 | 1 |
| DENILEUKIN DIFTITOX | 4 | 1 |
| ERLOTINIB | 4 | 1 |
| GRANISETRON | 4 | 1 |
| OXALIPLATIN | 4 | 1 |
| TOPOTECAN HYDROCHLORIDE | 4 | 1 |
| VELIPARIB | 3 | 2 |
| ACETYLCARNITINE | 3 | 1 |
| PACLITAXEL POLIGLUMEX | 3 | 1 |
| ADAVOSERTIB | 2 | 1 |
| SAPANISERTIB | 2 | 1 |
| CHEMBL3962632 | 0 | 1 |
| CHEMBL3991933 | 0 | 1 |
| CHEMBL399538 | 0 | 1 |